Nexalin Technology, Inc. (NXL)
NASDAQ: NXL · Real-Time Price · USD
0.9200
-0.0699 (-7.06%)
Dec 12, 2025, 4:00 PM EST - Market closed
Nexalin Technology Employees
Nexalin Technology had 6 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
6
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$26,155
Profits / Employee
-$1,446,485
Market Cap
17.16M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6 | 0 | - |
| Dec 31, 2023 | 6 | 0 | - |
| Dec 31, 2022 | 6 | -4 | -40.00% |
| Dec 31, 2021 | 10 | 6 | 150.00% |
| Dec 31, 2020 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NXL News
- 10 days ago - Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer's Disease Program - GlobeNewsWire
- 11 days ago - Join Nexalin Technology's Exclusive Live Investor Webinar and Q&A Session on December 4 - GlobeNewsWire
- 24 days ago - Nexalin's 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity - GlobeNewsWire
- 4 weeks ago - Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel - GlobeNewsWire
- 5 weeks ago - Nexalin Technology's Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer's Disease and Dementia - GlobeNewsWire
- 6 weeks ago - Nexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel - GlobeNewsWire
- 7 weeks ago - Nexalin's DIFS™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer's and Dementia Across Three Peer-Reviewed Studies - GlobeNewsWire
- 2 months ago - Nexalin Technology Expands Scientific Advisory Board with Appointment of Dr. Robert Rothstein to Support Alzheimer's and Traumatic Brain Injury Programs - GlobeNewsWire